company background image
BCYC logo

Bicycle Therapeutics NasdaqGS:BCYC Stok Raporu

Son Fiyat

US$23.51

Piyasa Değeri

US$1.6b

7D

-3.9%

1Y

54.2%

Güncellenmiş

05 Nov, 2024

Veri

Şirket Finansalları +

Bicycle Therapeutics plc

NasdaqGS:BCYC Stok Raporu

Piyasa değeri: US$1.6b

BCYC Stoklara Genel Bakış

Klinik aşamada bir biyofarmasötik şirketi olan Bicycle Therapeutics plc, Amerika Birleşik Devletleri ve Birleşik Krallık'ta mevcut terapötikler tarafından yetersiz hizmet verilen hastalıklar için bir ilaç sınıfı geliştirmektedir.

Bicycle Therapeutics plc Rakipler

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Bicycle Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse FiyatıUS$23.51
52 Haftanın En Yüksek SeviyesiUS$28.67
52 Haftanın En Düşük SeviyesiUS$12.54
Beta0.89
11 Aylık Değişim-0.38%
3 Aylık Değişim4.26%
1 Yıllık Değişim54.16%
33 Yıllık Değişim-59.43%
5 Yıllık Değişim188.82%
Halka arzdan bu yana değişim95.92%

Son Haberler & Güncellemeler

Bicycle Therapeutics plc (NASDAQ:BCYC) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Nov 03
Bicycle Therapeutics plc (NASDAQ:BCYC) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Bicycle Therapeutics (NASDAQ:BCYC) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Oct 23
Bicycle Therapeutics (NASDAQ:BCYC) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Recent updates

Bicycle Therapeutics plc (NASDAQ:BCYC) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Nov 03
Bicycle Therapeutics plc (NASDAQ:BCYC) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Bicycle Therapeutics (NASDAQ:BCYC) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Oct 23
Bicycle Therapeutics (NASDAQ:BCYC) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Bicycle Therapeutics Is Looking Increasingly Attractive

Aug 20

Bicycle Therapeutics Boosts Balance Sheet To Navigate Data Desert

May 24

Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why

May 10
Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why

Analysts' Revenue Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher

May 04
Analysts' Revenue Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher

Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?

Apr 19
Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?

Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point

Mar 12

Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely

Jan 04
Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely

Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts

Nov 07
Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts

The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts

May 14
The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts

Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%

Mar 31
Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%

Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?

Mar 09
Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?

Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook

Nov 08
Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook

Bicycle Therapeutics: Exploring An Intriguing Developmental Platform

Oct 08

Bicycle Therapeutics initiated Outperform at Cowen citing drug platform

Aug 31

Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration

Jul 12

Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?

Jul 10
Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?

Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer

Jul 05

Bicycle Therapeutics: Trying To Catch This Falling Knife

Apr 17

Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?

Apr 11
Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?

Bicycle Therapeutics: A Buy Ahead Of AACR Presentation

Mar 25

Bicycle Therapeutics: An Oncology Play With Big Potential

Feb 28

Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?

Nov 07
Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?

Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles

Aug 25

The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically

Aug 07
The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically

News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts

May 08
News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts

Hissedar Getirileri

BCYCUS BiotechsUS Pazar
7D-3.9%0.6%-0.8%
1Y54.2%21.4%31.5%

Getiri vs. Endüstri: BCYC geçen yıl % 21.4 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: BCYC geçen yıl % 31.5 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is BCYC's price volatile compared to industry and market?
BCYC volatility
BCYC Average Weekly Movement10.0%
Biotechs Industry Average Movement9.5%
Market Average Movement6.0%
10% most volatile stocks in US Market15.1%
10% least volatile stocks in US Market2.8%

İstikrarlı Hisse Senedi Fiyatı: BCYC hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: BCYC 'nin haftalık oynaklığı ( 10% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

KurulduÇalışanlarCEOWeb sitesi
2009284Kevin Leewww.bicycletherapeutics.com

Klinik aşamada bir biyofarmasötik şirketi olan Bicycle Therapeutics plc, Amerika Birleşik Devletleri ve Birleşik Krallık'ta mevcut terapötikler tarafından yetersiz hizmet verilen hastalıklar için bir ilaç sınıfı geliştirmektedir. Ürün hattı, yüksek nektin-4 eksprese eden tümörlerin tedavisi için faz I/II/III klinik çalışmada olan bir bisiklet toksin konjugatı (BTC) olan BT8009'u; Ephrin tip A reseptör 2 eksprese eden tümörün tedavisi için faz I/II klinik çalışmada olan bir BTC olan BT5528'i içermektedir; BT7480, Nectin-4'ü hedefleyen ve CD137'yi agonize eden faz I/II'de bir Bicycle TICA molekülü; ve BT7455, Ephrin tip A reseptör 2 ve CD137'yi hedefleyen bir Bicycle TICA molekülü ve preklinik denemede. Şirket ayrıca, Membran Tip 1 matris metaloproteaz eksprese eden tümörleri hedefleyen Faz I/IIa klinik çalışmalarında olan bir bisiklet toksin konjugatı (BTC) olan BT1718'i; ve ilerlemiş solid tümörleri tedavi etmek için faz IIa'da olan multivalent bir bisiklet CD137 agonisti olan BT7401'i geliştirmektedir.

Bicycle Therapeutics plc Temel Bilgiler Özeti

Bicycle Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
BCYC temel i̇stati̇sti̇kler
Piyasa değeriUS$1.62b
Kazançlar(TTM)-US$166.28m
Gelir(TTM)US$36.90m

44.0x

P/S Oranı

-9.8x

F/K Oranı

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
BCYC gelir tablosu (TTM)
GelirUS$36.90m
Gelir MaliyetiUS$167.89m
Brüt Kâr-US$130.99m
Diğer GiderlerUS$35.29m
Kazançlar-US$166.28m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)-2.41
Brüt Marj-355.00%
Net Kâr Marjı-450.64%
Borç/Özkaynak Oranı4.9%

BCYC uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün